Get started

Therapeutics

Esperion Therapeutics Analyst Ratings In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease. Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. (tipranks.com) Analyst ratings: 11/10/2020 Credit Suisse Group $45.00 10/15/2020 Bank of America $52.00 9/29/2020 JPMorgan Chase & Co. $35.00 8/11/2020 Needham & Company LLC $158.00 8/10/2020 Stifel Nicolaus $75.00 Today`s price: usd27.71 Please leave me a message if you want to test the buy and sell indicators that i am using.
NASDAQ:ESPRLong
by BuySellMarketMaker
Why I am Long on $MMEDFRight now one of the stocks that have my attention, (partly because of Kevin O'Leary) and the rest of its history is Mind Medicine (MindMed Inc.) They are one of the first companies finding a way to neutralize LSD while working on a DMT based therapy drug. Also, the market cap and entry is low. This is one of those stocks where you need to dig deep into the pitch deck and look at competition, market opportunities, and entry price. Right now as a biotech company, it is one of my favorite low priced biotech stocks, and as a long hold in somebody's portfolio, I don't think the risk aversion is too high. That being said, everything I say is on an opinion based basis. Please proceed with caution and invest at your own risk. Do your own due diligence.
MLong
by gamer456148
1
UMRX a top quarterly gainer,rising +850%.Expect Uptrend reversalUnum Therapeutics (UMRX, $3.32) was one of top quarterly gainers, jumping +850.2% to $3.32 per share. Tickeron A.I.dvisor analyzed 382 stocks in the Biotechnology Industry over the last three months, and discovered that 327 of them (85.6%) charted an Uptrend while 55 of them (14.4%) trended down. Tickeron A.I.dvisor found 51 similar cases when UMRX's price went up 15% within three months. In 51 out of those 51 cases, UMRX's price went down during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend reversal for UMRX are 90%. The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. Tickeron AI shows that in 12 of 13 cases where UMRX's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 90%.
UShort
by tickeron
RVVTF REVIVE THERAPEUTICS LTD upside potentialREVIVE THERAPEUTICS has a Market Capitalization of only 27.158M, while the Net Income (FY) reveals a debt, -1.028M. Some analists predict an Average Target Price of 2.36 usd. The indicators are bullish on most timeframes. Still a lot of room to grow, with that huge volume. If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, like others, just leave me a P.M.
OTC:RVVTFLong
by TopgOptions
7
100% Buy Signal on CRSPThe Megalodon indicators are giving us a buy signal on CRSP Therapeutics! The backtesting results are 100% on this stock so don't miss out on these profits! The Megalodon indicator uses a machine learning algorithm, combined with data from over 500 buy setups, and over 2000 indicators to produce extremely accurate buy signals on any and all asset classes! You will also receive real time buy and sell signals for the stock market, cryptocurrency, as well as forex markets! We also busy completed our cryptocurrency automated trade bot. It trades for you, using our backtested indicator with phenomenal results! So try it today!!!
NASDAQ:CRSPLong
by RandallGurule
1
$AITB - AIT Therapeutics Inc - Buy AlertAIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and for nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com
ALong
by TradeForProfits